ENDPOINTS

#AACR25: Boehringer’s updated results in HER2-mutated lung cancer impress

CHICAGO — Boehringer Ingelheim’s targeted lung cancer drug led to durable responses, according to the latest data from the early-stage trial. The German drugmaker is studying zongertinib in lung cancer with HER2 mutations, which account ...

Apr 28, 2025 - 15:00
 0
#AACR25: Boehringer’s updated results in HER2-mutated lung cancer impress
CHICAGO — Boehringer Ingelheim’s targeted lung cancer drug led to durable responses, according to the latest data from the early-stage trial. The German drugmaker is studying zongertinib in lung cancer with HER2 mutations, which account ...
Read More

Tags:

Previous Article

How will a global trade war shape the future of cyber leadership?

Next Article

Value-Based Care Gets Real

Related Posts

Merck KGaA closes in on SpringWorks deal at $3.5B price point

Merck KGaA closes in on SpringWorks deal at $3.5B price...

Apr 25, 2025  0

Novavax responds to FDA's request for new Covid vaccine trial

Novavax responds to FDA's request for new Covid vaccine...

Apr 28, 2025  0

Vaccine makers stand by their investments despite US headwinds

Vaccine makers stand by their investments despite US he...

Apr 23, 2025  0